Ray Gerald L & Associates Ltd. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 37,070 shares of the pharmaceutical company’s stock after selling 300 shares during the period. Ray Gerald L & Associates Ltd.’s holdings in Vertex Pharmaceuticals were worth $4,777,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of VRTX. BlackRock Inc. boosted its position in Vertex Pharmaceuticals by 2,699.4% in the first quarter. BlackRock Inc. now owns 19,246,380 shares of the pharmaceutical company’s stock valued at $2,104,591,000 after buying an additional 18,558,874 shares during the period. Jennison Associates LLC boosted its position in shares of Vertex Pharmaceuticals by 253.8% in the second quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after buying an additional 3,626,368 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,474,890 shares of the pharmaceutical company’s stock valued at $1,801,530,000 after buying an additional 560,796 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new position in shares of Vertex Pharmaceuticals during the first quarter valued at about $46,278,000. Finally, Marshall Wace North America L.P. bought a new position in shares of Vertex Pharmaceuticals during the first quarter valued at about $46,278,000. Institutional investors own 92.87% of the company’s stock.

Vertex Pharmaceuticals Incorporated (VRTX) opened at 152.96 on Tuesday. The stock has a market cap of $38.56 billion, a P/E ratio of 146.94 and a beta of 1.77. The stock has a 50 day moving average of $149.67 and a 200-day moving average of $120.19. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.33. The business had revenue of $544.10 million for the quarter, compared to analysts’ expectations of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.24 earnings per share. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current year.

WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/29/ray-gerald-l-associates-ltd-has-4-78-million-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Several brokerages have recently issued reports on VRTX. UBS AG restated a “buy” rating and issued a $135.00 target price (up previously from $132.00) on shares of Vertex Pharmaceuticals in a report on Friday, May 19th. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. Cowen and Company restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Jefferies Group LLC restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 22nd. Finally, Maxim Group set a $195.00 target price on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. Six analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $162.88.

In related news, EVP Stuart A. Arbuckle sold 70,969 shares of the firm’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $128.06, for a total value of $9,088,290.14. Following the transaction, the executive vice president now owns 145,061 shares in the company, valued at $18,576,511.66. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Ian F. Smith sold 4,250 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $155.39, for a total value of $660,407.50. Following the completion of the transaction, the chief financial officer now owns 120,138 shares in the company, valued at approximately $18,668,243.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 751,042 shares of company stock worth $113,078,257. 1.80% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.